

2018 Workshop
Viruses, Genes and Hematological Cancer
XV European LeukemiaNet Symposium



Istituto Veneto
di Scienze Lettere
ed Arti

Scientific Committee

Luigi Chieco-Bianchi

Vincenzo Ciminale

Donna M. D'Agostino

Genoveffa Franchini

Rüdiger Hehlmann

Local Organizing Committee

Alberto Amadori

Ilaria Cavallari

Luigi Chieco-Bianchi

Antonio Metrangolo

Micol Silic-Benussi

Contributors

Istituto Oncologico Veneto, IRCCS

European LeukemiaNet Foundation

Associazione Italiana contro le Leucemie-Linfomi e Mieloma, Sezione Venezia

Dipartimento di Scienze Chirurgiche,

Oncologiche e Gastroenterologiche, Università di Padova

Istituto Veneto di Scienze, Lettere ed Arti

International Workshop on Viruses, Genes and Hematological Cancer,
in conjunction with the 15th European LeukemiaNet Symposium



Department of Surgery,
Oncology and Gastroenterology
University of Padova



Istituto Oncologico
Veneto-IRCCS
Padova, Italy



2018 Workshop
Viruses, Genes and Hematological Cancer
XV European LeukemiaNet Symposium

March 19-22, 2018

Istituto Veneto di Scienze, Lettere ed Arti,
Palazzo Franchetti,
Campo Santo Stefano, Venezia, Italia

MONDAY, MARCH 19

13:45-14:45

Registration

14:45-15:20

Opening remarks

15:20-17:20

Session 1 – Viruses and leukemia/lymphoma.

Chairpersons: **Anita De Rossi** (University of Padova/IOV, Padova, Italy) and **Giuseppe Opocher** (University of Padova/IOV, Padova, Italy)

20'

Charles R.M. Bangham (Imperial College, London, UK): *'Regulation of latency in the human leukaemia virus HTLV-1'*

20'

Roberto S. Accolla (University of Insubria, Varese, Italy) *'Oncoproteins of Human T cell leukemia/Lymphoma Virus-1 (HTLV-1) and their involvement in HTLV-1-associated diseases'*

20'

Anne Van den Broeke (Jules Bordet Institute, ULB, Brussels/GIGA, Ulliège, Liège, Belgium) *'HTLV-1/BLV genomics: towards a better understanding of leukemia progression'*

20'

Silvia Giunco (IOV, Padova, Italy) *'EBV-driven lymphomagenesis: cross-talk between EBV and telomerase'*

20'

Giovanna Tosato (National Cancer Institute, NIH, Bethesda, U.S.A.) *'Evidence for a mesothelial origin of primary effusion lymphoma'*

20'

Ute Fischer (Heinrich-Heine-University, Düsseldorf, Germany) *'Infection as a cause of childhood leukemia ?'*

17:20-17:40

Coffee break

17:40-18:20

Keynote Lecture – **Robert Gallo** (Institute of Human Virology, Baltimore, U.S.A.)

'Nightmares of an Aging Viral Oncologist'

Introduction by **Luigi Chieco-Bianchi** (University of Padova, Italy)

18:45-19:45

Visit to the exhibition "**il mondo che non c'era**"
– the Ligabue Collection of pre-Columbian art.
Palazzo Loredan

TUESDAY, MARCH 20

8:40-10:20

Session 2 – Immunology and microenvironment.

Chairpersons:

Genoveffa Franchini (National Cancer Institute, NIH, Bethesda, U.S.A.) and **Guido Poli** (San Raffaele Scientific Institute, Milan, Italy)

20'

Luigi Buonaguro (Istituto Nazionale Tumori, Naples, Italy) '*Development of a therapeutic cancer vaccine for hepatitis-related cancers*'

20'

Genoveffa Franchini (National Cancer Institute, NIH, Bethesda, U.S.A.) '*Trained Immunity in protection against HIV*'

20'

Anna Aldovini (Harvard Medical School, Boston, U.S.A.) '*Impact of in vivo p38 MAPK inhibition on SIV-mediated immune activation*'

20'

Maurizio Zanetti (University of California San Diego, La Jolla, U.S.A.) '*Cell nonautonomous ER stress in the tumor microenvironment*'

20'

Antonio Rosato (University of Padova/IOV, Padova, Italy) '*Antigen-specific redirection of Cytokine-Induced Killer (CIK) cells as a valuable alternative to CAR-T therapy*'

10:20-10:50

Coffee break

10:50-12:30

Session 3 – Genetics and epigenetics.

Chairpersons: **Federico Caligaris-Cappio** (AIRC, Milan, Italy) and **Alberto Amadori** (University of Padova/IOV, Padova, Italy)

20'

Jürgen Ruland (Technische Universität, München, Germany) '*Antigen receptor and co-receptor signaling pathways in lymphoma: the dark side*'

- 20' **Riccardo Dalla-Favera** (Columbia University, New York, U.S.A.) *'New pathogenetic and therapeutic insights in diffuse large B-cell lymphoma'*
- 20' **Pier Giuseppe Pelicci** (Milan University/EIO, Milan, Italy) *'Regulation of cancer stem cell functions by environmental signals'*
- 20' **Erich Piovan** (University of Padova, Italy) *'Role of Hedgehog signaling in T-cell acute lymphoblastic leukemia'*
- 20' **Neal S. Young** (National Heart, Lung and Blood Institute, NIH, Bethesda, U.S.A.) *'Clonality in context'*
-
- 12:30-14:00 Lunch
-
- 14:00- 15:40 **Session 4 - Novel therapeutic targets and strategies.**
Chairpersons: **Franco Buonaguro** (Istituto Nazionale Tumori, Naples, Italy) and **Donna D'Agostino** (University of Padova, Italy)
- 20' **Luca Scorrano** (University of Padova/VIMM, Padova, Italy) *'The role of the mitochondria cristae shaping protein Opa 1 in lymphoma'*
- 20' **Vincenzo Ciminale** (University of Padova/IOV, Padova, Italy) *'Mitochondrial reactive oxygen species prime T-ALL cells to apoptosis by engaging the OMA1-OPA1 axis'*
- 20' **Ildikò Szabò** (University of Padova, Italy) *'Pharmacological targeting of a mitochondrial ion channel against chronic lymphocytic leukemia'*
- 20' **Meike Vogler** (Goethe University Frankfurt, Germany) *'Mitochondrial priming and BH3-mimetics in lymphoid malignancies'*

TUESDAY, MARCH 20

- 20' **Andrea Rasola** (University of Padova, Italy) *'Targeting the metabolic liabilities of B-cell chronic lymphocytic leukemia'*
-
- 15:40-16:00 Coffee Break
-
- 16:00-17:40 **Session 4 (continued).**
Chairpersons: **Gianpiero Semenzato** (University of Padova, Italy) and **Maria Grazia Romanelli** (University of Verona, Italy)
- 20' **Carlo Croce** (Ohio State University, Columbus, U.S.A.) *'MicroRNA dysregulation to identify therapeutic targets'*
- 20' **Stefano Indraccolo** (IOV, Padova, Italy) *'Histone deacetylase inhibitors and Notch signaling in T-cell acute lymphoblastic leukemia'*
- 20' **Giuseppe Basso** (University of Padova, Italy) *'Personalized therapy in resistant childhood ALL'*
- 20' **Francesco Piazza** (University of Padova/VIMM, Padova, Italy) *'Protein kinases CK1 and CK2 in B-cell malignancies'*
- 20' **Olivier Hermine** (Hôpital Necker, Paris, France) *'HCV-related B-cell lymphoma physiopathology and therapeutic implications'*
-
- 19:30 Social Dinner
-

WEDNESDAY, MARCH 21

15TH EUROPEAN LEUKEMIANET SYMPOSIUM

10:00 - 10:30

Coffee Break

10:30 - 12:00

Main Session – Sala del Portego
Keynote lectures and Merit Awards
R. Hehlmann, L. Chieco-Bianchi

10'

Welcome and Introduction
ELN Merit Awards to S. Saußebe and U. Berger
R. Hehlmann

20'

Minimal residual disease (MRD) in acute myeloid leukemia (AML): can it already serve as a surrogate for survival ?
G. Ossenkoppele

20'

The new ELN management recommendations for myeloproliferative neoplasms (MPN)
G. Barosi

20'

CAR-T-cells in hematologic neoplasias
C. Rössig

20'

50 years of chronic myeloid leukemia (CML) research: where do we stand today ?
M. Baccarani

12:00 - 13:00

Lunch

13:00 - 15:00

Acute myeloid leukemia (AML)/Minimal residual disease (MRD) WP5/WP12/WP10 – MRD on the way to surrogacy
G. Ossenkoppele, C. Thiede

24'

Introduction for the Munich meeting
G.J. Schuurhuis

WEDNESDAY, MARCH 21

Parallel Session – Sala del Giardino

Chairs/Contributors

| | |
|---------------|---|
| 9:00 - 10:00 | ELN Steering Committee Meeting (ELN lead participants only) |
| 10:00 - 10:30 | Coffee Break |
| 12:00 - 13:00 | Lunch |
| 13:00 - 15:00 | <i>Myeloproliferative neoplasia (MPN), WP9 - New projects</i> J. Kiladjian, T. Barbui |
| 15' | <i>The place of IFN in the management of MPNs and possible new clinical trials</i> J. Kiladjian |
| 15' | <i>ELN survey on DVT in MPN: background for new anticoagulants</i> T. Barbui |
| 15' | <i>New anticoagulants for the secondary prevention of venous thrombosis</i> M. Griesshammer |
| 15' | <i>Collaborative research on JAK2 V617F and KIT D816V cases</i> A. Reiter |
| 15' | <i>Clinical correlates of triple-negative patients with primary myelofibrosis</i> A. Vannucchi |
| 15' | <i>MPN Registry Research. Collaborative research potential</i> M. Björkholm |
| 15' | <i>New research platforms for the exploitation of individualized medicines</i> G. Barosi |

WEDNESDAY, MARCH 21

- 24' *Next generation sequencing (NGS) for MRD in AML*
P. Valk
- 24' *Molecular MRD general overview*
C. Thiede
- 24' *Automated analysis of MRD in AML*
F. Lacombe/M.C. Bené
- 24' *MRD on the way to surrogacy*
R. Walter
-
- 15:00 - 15:30 *Coffee Break*
-
- 15:30 - 18:00 *AML/MRD continued (WP5/WP12/WP10)*
- 24' *Discussion on other subtopics with short introductions*
G.J. Schuurhuis/M.C. Bené
- 24' *Requirements for multicenter studies*
M. Subklewe
- 24' *Peripheral blood MRD*
L. Maurillo
- 24' *Timepoints of interest*
J. Cloos
- 24' *Leukemia stem cells*
G.J. Schuurhuis
- 24' *Thresholds*
S. Freeman
- Discussants:*
C. Bloomfield, G. J. Schuurhuis, F. Lacombe, M.C. Bené, W. Kern, M. Subklewe, S. Freeman, J. Cloos, F. Buccisano, C. Thiede, P. Valk, M. Heuser, K. Döhner, B. van de Reijden, R. Walter, R. Hills, A. Venditti, G. Ossenkoppele, P. Vijas, J. Phillippe, R. Dillon, L. Maurillo

WEDNESDAY, MARCH 21

PARALLEL SESSION (continued)

- 15' *Spanish registry on polycythemia vera, essential thrombocytosis and myelofibrosis: a platform for collaboration*
A. Alvarez-Larrán
-
- 15:00 - 15:30 Coffee Break
-
- 15:30 - 17:30 *Chronic myeloid leukemia (CML), WP4 - The path to cure*
M. Baccarani, S. Saubele
- 15' *EURO-SKI (Stop Kinase Inhibitors) – What next ?*
S. Saubele
- 15' *Does the immune system contribute to treatment free remission ?*
S. Mustjoki
- 15' *Discussing the ELN recommendations*
M. Baccarani
- 15' *Updating the ELN recommendations for mutational analysis*
S. Soverini
- 15' *The definition of progression in the tyrosine kinase inhibitor (TKI) era*
M. Lauseker
- 15' *New TKIs, ABLOO1 (Asciminib)*
A. Hochhaus
- 15' *New TKIs, PF-116*
A. Turkina
- 15' *Determinants of survival and center effects in CML*
R. Hehlmann

THURSDAY, MARCH 22

Main Session – Sala del Portego Chairs/Contributors

- 8:30 - 10:30 *HARMONY Update with AML pilot working meeting*
J. Hernandez, L. Bullinger
- 30' *HARMONY 2018 - what has happened so far*
J. Hernandez
- 30' WP2 - update of the pilot study
L. Bullinger
- 30' *WP3/4 - HARMONY data platform update*
C. van Speybroeck, R. Medina
- 30' *Update on discussion of outcomes definitions*
Key Opinion Leaders
R. Hehlmann
-
- 10:30 - 11:00 Coffee Break
-
- 11:00 - 13:00 *HARMONY: AML pilot working meeting (WP1, WP2, WP3/4, WP5)*
L. Bullinger
- 120' Working group meeting with discussion what to do/adjust/etc.
- incorporation of first data set
- feedback on work-flow
- problems?
- adjustments needed?
- discussion of first data analysis steps
- 13:00 - 14:00 *General Assembly and summaries of the WP sessions*
R. Hehlmann

THURSDAY, MARCH 22

Parallel Session – Sala del Giardino Chairs/Contributors

- 8:30 - 10:30 *Stem cell transplantation (SCT), WP14*
D. Niederwieser, J. Apperley
- 17' *Alternative donor therapy for Thalassemia and SCT in pediatric patients*
J. de la Fuente
- 17' *Multiple myeloma, new projects*
G. Gahrton
- 17' *GvHD overview*
T. Ruutu
- 17' *CAR-T therapy, gene editing*
E. Ruggiero
- 17' *Randomized double blind placebo controlled mesenchymel stem cell (MSC) study for GvHD – Rethrim*
D. Niederwieser
- 17' *HCT vs CT: recruitment termination*
D. Niederwieser
- 17' *Education in SCT*
M. Aljurf
-
- 10:30 - 11:00 Coffee Break
-
- 11:00 - 13:00 *Acute lymphoblastic leukemia (ALL), WP6 - MRD guided treatment*
D. Hoelzer, R. Bassan
- 15' *First analysis of the GIMEMA LAL2116 frontline dasatinib-blinatumomab protocol for Philadelphia chromosome positive (Pb+) ALL patients*

THURSDAY, MARCH 22

10' *General Assembly: Report from the steering committee*
R. Hehlmann

8' *WP4*
M. Baccarani

8' *WP5*
G. Ossenkoppele

8' *WP6*
D. Hoelzer

8' *WP9*
T. Barbui

8' *WP14*
D. Niederwieser

8' *HARMONY*
J. Hernandez

14:00 **Small Farewell Lunch**

THURSDAY, MARCH 22

PARALLEL SESSION (continued)

- 15' **R. Foà**
First interim analysis (60 patients) of the Ph+ GRAAPH-2014 trial with nilotinib front-line
P. Rouselot
- 15' *Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Ph- ALL (PETHEMA)*
J.-M. Ribera
- 15' *Results of the GRAALL-2005 trial and the principle of the current GRAALL-2014 trial, all for Ph- ALL*
H. Dombret
- 15' *Final report on clinical outcomes by RALL-2009 protocol*
E. Parovichnikova
- 15' *Clofarabine-cyclophosphamide for Relapsed/Refractory ALL (GIMEMA)*
R. Bassan
- 15' *MRD response according to the genetic landscape of Ph-ALL patients enrolled in the GIMEMA LAL1913 protocol*
S. Chiaretti
- 15' *MRD dynamics on non-intensive but non-interruptive treatment*
O. Gavrulina
-
- 14:00 Small Farewell Lunch
-

Istituto Veneto di Scienze,
Lettere ed Arti
San Marco 2945
30124 Venezia
telefono +39 0412407711
fax +39 0415210598
ivsla@istitutoveneto.it
www.istitutoveneto.it